Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 21;31:09636897221102898. doi: 10.1177/09636897221102898

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Proteomic assessment of MSC^N-Exos and MSC^E-Exos. Proteins that were differentially expressed (absolute fold change ≥ 1.5 and P < 0.05) in MSC^E-Exos relative to MSC^N-Exos were subjected to gene ontology term enrichment analyses. (A) Angiogenesis-related biological processes are shown. n = 3 per group. (B) The number of proteins with expression change, comparing between indicated treatment groups. (C) The ratio of angiogenesis-related protein levels in MSC^E-Exos as compared with levels in MSC^N-Exos (n = 3/group). (D) DMBT1, VEGF, and CD63 protein levels in MSC^E-Exos and MSC^N-Exos as assessed via Western blotting (n = 3/group). DMBT1, deleted in malignant brain tumors 1; VEGF, vascular endothelial growth factor.